본문 바로가기
KERD
논문KCI 등재

Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B

김형우|최용선|원정호|허진영|박상종|박영민|손원|유선홍|이재민
대한간학회 (The korean Association for the Study of the Liver)|2016.09|Clinical and Molecular Hepatology|제22권 제3호|pp. 339-349

0

조회

0

다운로드

4

인용

0

참고문헌

키워드

ObesityHepatocellular carcinomaChronic hepatitis BAntiviral treatment

초록

Background/Aims: This study aimed to clarify the effect of obesity on the development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients receiving antiviral treatment. Methods: This study applied a retrospective analysis to a historical cohort in Bundang Jesaeng Hospital. In total, 102 CHB patients were treated with entecavir as an initial treatment for CHB and checked for obesity using a body composition analyzer. Hepatic steatosis was measured semiquantitatively using Hamaguchi’s scoring system in ultrasonography. Risk factors for the development of HCC were analyzed, including obesity-related factors (body mass index [BMI], waist circumference [WC], waist-to-hip ratio [WHR], visceral fat area [VFA], and hepatic steatosis). Results: The median follow-up duration of the patients was 45.2 months (interquartile range: 36.0-58.3 months). The cumulative incidence rates of HCC at 1 year, 3 years, and 5 years were 0%, 5.3%, and 9.0%, respectively. Univariable analysis revealed that the risk factors for HCC development were a platelet count of <120,000 /mm2 (hazard ratio [HR]=5.21, P=0.031), HBeAg negativity (HR=5.61, P=0.039), and liver cirrhosis (HR=10.26, P=0.031). Multivariable analysis showed that the significant risk factor for HCC development was liver cirrhosis (HR=9.07, P=0.042). However, none of the obesity-related risk factors were significantly associated with HCC: BMI ≥25 kg/m2 (HR=0.90, P=0.894), WC ≥90 cm (HR=1.10, P=0.912), WHR ≥0.9 (HR=1.94, P=0.386), VFA ≥100 cm2 (HR=1.69, P=0.495), and hepatic steatosis (HR=0.57, P=0.602). Conclusions: HCC development is associated with liver cirrhosis but not obesity-related factors in CHB patients receiving entecavir. (Clin Mol Hepatol 2016;22:339-349)

Abstract

Background/Aims: This study aimed to clarify the effect of obesity on the development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients receiving antiviral treatment. Methods: This study applied a retrospective analysis to a historical cohort in Bundang Jesaeng Hospital. In total, 102 CHB patients were treated with entecavir as an initial treatment for CHB and checked for obesity using a body composition analyzer. Hepatic steatosis was measured semiquantitatively using Hamaguchi’s scoring system in ultrasonography. Risk factors for the development of HCC were analyzed, including obesity-related factors (body mass index [BMI], waist circumference [WC], waist-to-hip ratio [WHR], visceral fat area [VFA], and hepatic steatosis). Results: The median follow-up duration of the patients was 45.2 months (interquartile range: 36.0-58.3 months). The cumulative incidence rates of HCC at 1 year, 3 years, and 5 years were 0%, 5.3%, and 9.0%, respectively. Univariable analysis revealed that the risk factors for HCC development were a platelet count of <120,000 /mm2 (hazard ratio [HR]=5.21, P=0.031), HBeAg negativity (HR=5.61, P=0.039), and liver cirrhosis (HR=10.26, P=0.031). Multivariable analysis showed that the significant risk factor for HCC development was liver cirrhosis (HR=9.07, P=0.042). However, none of the obesity-related risk factors were significantly associated with HCC: BMI ≥25 kg/m2 (HR=0.90, P=0.894), WC ≥90 cm (HR=1.10, P=0.912), WHR ≥0.9 (HR=1.94, P=0.386), VFA ≥100 cm2 (HR=1.69, P=0.495), and hepatic steatosis (HR=0.57, P=0.602). Conclusions: HCC development is associated with liver cirrhosis but not obesity-related factors in CHB patients receiving entecavir. (Clin Mol Hepatol 2016;22:339-349)

참고문헌 (37)

  1. Tsukuma H, "Risk factors for hepatocellular carcinoma among patients with chronic liver disease", N Engl J Med, 328, pp.1797~1801 (1993)
  2. Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease", N Engl J Med, 351, pp.1521~1531 (2004)
  3. Hosaka T, "Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection", Hepatology, 58, pp.98~107 (2013)
  4. Lim YS, "Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine", Gastroenterology, 147, pp.152~161 (2014)
  5. European Association For The Study Of The Liver, "EASL clinical practice guidelines: management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
  6. Terrault NA, "AASLD guidelines for treatment of chronic hepatitis B", Hepatology, 63, pp.261~283 (2016)
  7. Cho JY, "Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.", Gut, 63, pp.1943~1950 (2014)
  8. Renehan AG, "Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies", Lancet, 371, pp.569~578 (2008)
  9. Calle EE, "Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults", N Engl J Med, 348, pp.1625~1638 (2003)
  10. Goodwin PJ, "Impact of the obesity epidemic on cancer", Annu Rev Med, 66, pp.281~296 (2015)
  11. Saunders D, "Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence", Aliment Pharmacol Ther, 31, pp.1051~1063 (2010)
  12. Michelotti GA, "NAFLD, NASH and liver cancer", Nat Rev Gastroenterol Hepatol, 10, pp.656~665 (2013)
  13. Ohki T, "Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients", Clin Gastroenterol Hepatol, 6, pp.459~464 (2008)
  14. Chen CL, "Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B", C infection: a follow-up study in Taiwan, 2008, pp.135, 111~121
  15. Bruix J, "Practice Guidelines Committee. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma", Hepatology, 42, pp.1208~1236 (2005)
  16. Korean Association for the Study of the Liver, "KASL Clinical Practice Guidelines: Management of chronic hepatitis B", Clin Mol Hepatol, 18, pp.109~162 (2012)
  17. Nishiura T, "Ultrasound evaluation of the fibrosis stage in chronic liver disease by the simultaneous use of low and high frequency probes", Br J Radiol, 78, pp.189~197 (2005)
  18. Chalasani N, "The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association", Hepatology, 55, pp.2005~2023 (2012)
  19. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A., "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)", JAMA, 285, pp.2486~2497 (2001)
  20. Grundy SM, "Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute", American Heart Association conference on scientific issues related to definition, 2004, pp.109, 433~438
  21. Hamaguchi M, "The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation", Am J Gastroenterol, 102, pp.2708~2715 (2007)
  22. Viera AJ, "Understanding interobserver agreement: the kappa statistic", Fam Med, 37, pp.360~363 (2005)
  23. Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
  24. Ohki T, "Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH", Gut, 58, pp.839~844 (2009)
  25. Mathur A, "Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma", HPB (Oxford), 15, pp.504~510 (2013)
  26. Wang H, "Liver resection in hepatitis B-related hepatocellular carcinoma: clinical outcomes and safety in overweight and obese patients", PLoS One, 9, pp.e99281~ (2014)
  27. Wong GL, "Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B", Gut, 58, pp.111~117 (2009)
  28. Chao LT, "Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort", Carcinogenesis, 32, pp.876~881 (2011)
  29. Adami HO, "Excess risk of primary liver cancer in patients with diabetes mellitus", J Natl Cancer Inst, 88, pp.1472~1477 (1996)
  30. Wideroff L, "Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark", J Natl Cancer Inst, 89, pp.1360~1365 (1997)
  31. El-Serag HB, "Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma", Gastroenterology, 126, pp.460~468 (2004)
  32. Fu SC, "Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with new onset diabetes: a nationwide cohort study", Aliment Pharmacol Ther, 41, pp.1200~1209 (2015)
  33. Wang CS, "The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses", Cancer Epidemiol Biomarkers Prev, 18, pp.2054~2060 (2009)
  34. Cindoruk M, "Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection", J Clin Gastroenterol, 41, pp.513~517 (2007)
  35. Wong VW, "Hepatitis B virus infection and fatty liver in the general population", J Hepatol, 56, pp.533~540 (2012)
  36. Cheng YL, "Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up", PLoS One, 8, pp.e72049~ (2013)
  37. Machado MV, "Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients", J Gastroenterol Hepatol, 26, pp.1361~1367 (2011)

관련 논문AI추천

Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B김광일, 김미나, 전영은, 하연정, 황성규, Hana Park, Joo Ho Lee, Kyu Sung Rim, Soo-Hwan Kim, Yun Bin Lee대한간학회 · Clinical and Molecular Hepatology2019 · 제25권 제1호Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis권오상, 김정한, Jung Young Kul, Kim Ju Hyun, Kim Yun Soo, Lee Chan Uk, Shin Seung Kak, Suh Sang Jun, Yeon Jong Eun, Yim Hyung Joon거트앤리버 소화기연관학회협의회 · Gut and Liver2021 · 제15권 제3호Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir김도영, 김범경, 김승업, 박준용, 안상훈, 이혜원, 한광협, David Sooik Kim, Mi Young Jeon대한간학회 · Clinical and Molecular Hepatology2019 · 제25권 제3호Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B손원, 김지훈, 김형준, 백용한, 우민아, 이정일, 정신호, 조주연대한간학회 · Clinical and Molecular Hepatology2017 · 제23권 제2호Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infectionByung Ik Kim, Chang Wook Chon, Hong Joo Kim, Hyo Sun Seok, Won Gil Chung, Yong Kyun Cho, Young Gil Choe, Young Yool Koh대한간학회 · Clinical and Molecular Hepatology2012 · 제18권 제2호Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analoguesAdrian Gadano, Akito Nozaki, Chao Wu, Cheng-Hao Tseng, Chia-Yen Dai, Chung-Feng Huang, Dae Won Jun, Daniel Q. Huang, Eileen Yoon, Gi-Ae Kim, Haruki Uojima, Hidenori Toyoda, Hirokazu Takahashi, Hiroshi Abe, Huy Trinh, Hyunwoo Oh, Jang Han Jung, Jee-Fu Huang, Jie Li, Joanne Kimiko Liu, Kaori Inoue, Keigo Kawashima, Koichi Takaguchi, Kunihiko Tsuji, Masanori Atsukawa, Masaru Enomoto, Masatoshi Ishigami, Mindie H. Nguyen, Ming-Lung Yu, Ming-Lun Yeh, Norio Itokawa, Pei-Chien Tsai, Philip Vutien, Ramsey Cheung, Ritsuzo Kozuka, Rui Huang, Sang Bong Ahn, Sebastián Marciano, Soung Won Jeong, Sung Eun Kim, Takashi Honda, Tomonori Senoh, Toru Ishikawa, Tsunamasa Watanabe, Wan-Long Chuang, Yao-Chun Hsu, Yasuhito Tanaka대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제3호

이 간행물의 다른 논문 (7건)

Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment최규용, 김홍주, 박수경, 전우규, 양효준, 정윤석, 박정호, 박동일, 조용균, 손정일, 김병익pp. 350-358Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis전예주, 장은선, 최윤숙, 김진욱, 정숙향pp. 359-365Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection정보현, 이남준, 권준혁, 황신, 김종만, 이해원, 서경석, 조재원, 이석구, 이성규, 이광웅, 송기원pp. 366-371Decreased C-reactive protein induces abnormal vascular structure in a rat model of liver dysfunction induced by bile duct ligation김기진, 최종호, 배시현, 오세훈, 전지혜pp. 372-381Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B엄순호, 안형인, 이한아, 연종은, 정영걸, 서연석, 박상정, 변관수, 서상준, 박승운, 임형준, 김태형, 김지훈pp. 382-389
원문 보기